Prasco to market authorized generic Vancocin

Company makes agreement with ViroPharma

CINCINNATI — Prasco Labs will market an authorized generic version of a drug used to treat diarrhea caused by a bacterial infection, the company said Wednesday.

Prasco announced that it had signed a deal with ViroPharma to market an authorized generic version of Vancocin (vancomycin hydrochloride) capsules in the 125-mg and 250-mg strengths. The drug is used to treat diarrhea related to Clostridium difficile infection.

The news follows Watson's announcement Tuesday that the Food and Drug Administration had approved its generic version of Vancocin. Unlike generic drugs, authorized generics are branded drugs marketed under their generic names at a reduced price under agreements between the original branded drug's manufacturer and an outside company.

Vancocin had sales of $332 million during the 12-month period ended in February, according to IMS Health.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.